UPCOMING/ WENDESDAY, AUGUST 13

Using single cell RNA sequencing to identify novel lipid nanoparticle candidates with Dr. Kalina Paunovska, co-founder of Nava Therapeutics.

Efficient delivery of RNA therapeutics remains a central challenge in the field of drug delivery, particularly due to biological barriers that limit biodistribution and functional uptake across diverse cell types. Lipid nanoparticles (LNPs) offer a promising platform to address these limitations; however, their clinical translation is often hindered by an incomplete understanding of how cellular heterogeneity impacts delivery efficiency. In this webinar, Dr. Kalina Paunovska will examine these challenges and present SENT-seq (Single-cell Nanoparticle Targeting-sequencing), a high-throughput, single-cell multiomic screening platform designed to quantify LNP biodistribution, mRNA translation, and transcriptomic response in vivo. This approach enables the unbiased identification of cell subsets with distinct uptake and delivery profiles and reveals molecular signatures associated with enhanced or impaired LNP-mediated delivery. The webinar will discuss how SENT-seq addresses key limitations in nanoparticle screening and supports the rational design of novel LNPs tailored to specific cell types and therapeutic applications.

Click to register